Decitabine disrupts EBV genomic epiallele DNA methylation patterns around CTCF binding sites to increase chromatin accessibility and lytic transcription in gastric cancer

mBio. 2023 Oct 31;14(5):e0039623. doi: 10.1128/mbio.00396-23. Epub 2023 Aug 22.

Abstract

Epstein-Barr virus (EBV) latency is controlled by epigenetic silencing by DNA methylation [5-methyl cytosine (5mC)], histone modifications, and chromatin looping. However, how they dictate the transcriptional program in EBV-associated gastric cancers remains incompletely understood. EBV-associated gastric cancer displays a 5mC hypermethylated phenotype. A potential treatment for this cancer subtype is the DNA hypomethylating agent, which induces EBV lytic reactivation and targets hypermethylation of the cellular DNA. In this study, we identified a heterogeneous pool of EBV epialleles within two tumor-derived gastric cancer cell lines that are disrupted with a hypomethylating agent. Stochastic DNA methylation patterning at critical regulatory regions may be an underlying mechanism for spontaneous reactivation. Our results highlight the critical role of epigenetic modulation on EBV latency and life cycle, which is maintained through the interaction between 5mC and the host protein CCCTC-binding factor.

Keywords: CTCF; DNA methylation; Epstein-Barr virus; epigenetics; gastric cancer.

MeSH terms

  • Binding Sites
  • CCCTC-Binding Factor / genetics
  • CCCTC-Binding Factor / metabolism
  • Chromatin
  • DNA / metabolism
  • DNA Methylation
  • Decitabine / metabolism
  • Epstein-Barr Virus Infections*
  • Genomics
  • Herpesvirus 4, Human / physiology
  • Humans
  • Stomach Neoplasms*
  • Virus Latency / genetics

Substances

  • Chromatin
  • CCCTC-Binding Factor
  • Decitabine
  • DNA